An observational study in Aortic Stenosis, sponsored by Idoven 1903 S.L.. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Idoven 1903 S.L. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 4th largest by planned enrollment of the 98 observational ones that give a count, is one of 6 that started in 2026, is one of 98 observational ones, reaches primary completion later than 30 of the 57 other live ones, and was the 186th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Germany, Netherlands
Ages 70+
IHF GmbH - Institut für Herzinfarktforschung · Sites in Germany
Ages 18+
Institut für Pharmakologie und Präventive Medizin · Sites in Germany
Ages 18+
Ceric Sàrl · Sites in Germany, Austria, Estonia and 11 more countries
Ages 65–75
Novartis Pharmaceuticals · Sites in Germany, United States, Austria and 8 more countries
Ages 2–11
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 220 across the 93 interventional studies, 300 across the 98 observational. Of the 109 that completed or were terminated, 28 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 191 have an industry lead sponsor. The 10 most frequent:
Idoven 1903 S.L. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Idoven 1903 S.L. has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479992Idoven 1903 S.L.Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study | 2027-01 |
| NCT06493994University of LuebeckMyval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry | 2027-01-30 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
| NCT05603520Heinrich-Heine University, DuesseldorfPhenotyping Heterogeneity and Regionality of the Aorta | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AoS-SEDAI study is an observational, multicenter, retrospective and prospective clinical study.
This study aims to assess Willem Artificial Intelligence (AI) ability to distinguish between aortic stenosis (AS) and non-AS patients from 12-lead electrocardiogram (ECG) data.
Aortic Stenosis (AS) is a common and progressive valvular heart disease, especially in older adults, yet significantly underdiagnosed. Many individuals with significant AS may remain asymptomatic for extended periods or experience vague symptoms, delaying diagnosis for several years. In some cases, sudden cardiac events or decompensation may be the first indication of advanced AS, particularly in those who have not undergone regular cardiovascular evaluation.
The primary method for diagnosing AS is echocardiography, which allows visualization of valve anatomy and assessment of transvalvular gradients. However, reliance on symptom reporting or late-stage signs, that trigger a provider to order an echo, can result in missed opportunities for earlier detection. Additionally, electrocardiographic changes-such as left ventricular hypertrophy or strain patterns-can often be detected before structural abnormalities are visible on imaging studies. This delay between electrical changes evolution and later structural findings creates a valuable opportunity to intervene sooner, for example with a valve replacement. This diagnostic latency highlights a critical window where early identification through Artificial Intelligence (AI) analysis of electrocardiograms (ECGs) and timely referral to cardiology can significantly alter disease trajectory and improve outcomes, especially in primary care and community health settings.
AoS-SEDAI study is an observational, retrospective and prospective, multicenter clinical study. Even though controls will be distinguished from AS patients for ground truth and performance evaluation, this is a single-arm study since there are no differences in study interventions.
The target population consists of patients under assessment of Aortic Stenosis (AS).
Screened patients need to have 12-lead ECG recordings within 90 days of a transthoracic echocardiogram (TTE). In the case of multiple ECGs and TTEs per patient, all of them will be selected and analysed accordingly considering the corresponding PI diagnosis at each time. In the event of a patient with a different diagnosis over time (e.g. non-AS confirmed diagnosis later on diagnosed with AS), multiple timepoint ECGs will be categorized so that the same patient is not included both in the control and in the AS populations.
Controls will include non-AS patients with relevant TTE and clinical findings during AS differential diagnosis (such as hypertensive heart disease, structural heart diseases, hypertrophic cardiomyopathy among other cardiomyopathies, mild aortic stenosis, and no significant aortic leaflet calcification).
Inclusion Criteria:
No exclusion criteria are defined for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with an Aortic Stenosis diagnosis confirmed by the physician following their routine practice (e.g. ESC Guidelines), including complete clinical assessment with echocardiogram or other complementary techniques.
Device: Willem AI ECG assessment
Subjects without Aortic Stenosis confirmed by the physician after thorough evaluation following their routine practice.
Device: Willem AI ECG assessment
There is no study intervention. The Willem AI platform will assess all study electrocardiograms (ECGs) for the identification of aortic stenosis. Regardless of retrospective or prospective enrollment, Willem output will not be provided to the healthcare professional user for clinical evaluation, and therefore routine practice will not be impacted nor altered.
Willem performance to detect severe Aortic Stenosis
Performance of Willem AI platform to distinguish between severe Aortic Stenosis (AS) patients with confirmed diagnosis and non-AS patients, by means of the following performance metrics: Area Under the Receiver Operating Characteristic curve (AUROC), diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Standard Of Care (SOC) investigator diagnosis will be used as the ground truth.
Time frame: ECG will be performed at baseline, and ECG analysis by Willem AI will be performed retrospectively throughout the trial, and finalized upon recruitment completion.
Willem performance to detect moderate Aortic Stenosis
Performance of Willem AI platform to distinguish between moderate Aortic Stenosis (AS) patients with confirmed diagnosis and non-AS patients, by means of the following performance metrics: Area Under the Receiver Operating Characteristic curve (AUROC), diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Standard Of Care (SOC) investigator diagnosis will be used as the ground truth.
Time frame: ECG will be performed at baseline, and ECG analysis by Willem AI will be performed retrospectively throughout the trial, and finalized upon recruitment completion.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.
Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 9 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Jan 2027 and completion Dec 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idoven 1903 S.L.